Personalis, National Cancer Center Hospital East, and Ono Collaborate to Better Predict Immunotherapy Response for Rectal Cancer
Retrieved on:
Tuesday, May 16, 2023
Research, Hospitals, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, DNA, Principal investigator, Clinical trial, Cancer, Assistant Chief of the Naval Staff, Biomarker, Immunotherapy, PSNL, MRD, Ono, MD, Patient, National Cancer Center, R, Recurrence, Tumor microenvironment, Disease, Safety, Nivolumab, Pharmaceutical industry, Medical imaging, Chief Justice of Hungary, Neoplasm
Under the agreement, National Cancer Center Hospital East (NCCHE) will recruit patients and conduct the clinical trial, Ono will provide nivolumab, and Personalis will perform MRD and biomarker testing.
Key Points:
- Under the agreement, National Cancer Center Hospital East (NCCHE) will recruit patients and conduct the clinical trial, Ono will provide nivolumab, and Personalis will perform MRD and biomarker testing.
- Biomarker research will be conducted throughout the study, including sample analysis from both tumor lesion tissue and plasma circulating tumor DNA (ctDNA).
- Tissue samples will be analyzed by the Personalis ImmunoID NeXT ® platform to capture tumor molecular profile and tumor microenvironment features to better understand immunotherapy responses.
- These comprehensive assays may enable the selection of cases with high efficacies and will promote the non-operative management in dMMR rectal cancer.”